Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Avital Klein-Brill"'
Publikováno v:
Cancer Control, Vol 30 (2023)
Background FOLFOX (leucovorin calcium [folinic acid], fluorouracil, and oxaliplatin) combined with or without anti-VEGF therapy represents one of the primary first-line treatment options for metastatic colorectal carcinoma (mCRC). However, there is l
Externí odkaz:
https://doaj.org/article/ca3bb9fc6886422096be078845a74e18
Autor:
Jenia Gutin, Ronen Sadeh, Nitzan Bodenheimer, Daphna Joseph-Strauss, Avital Klein-Brill, Adi Alajem, Oren Ram, Nir Friedman
Publikováno v:
Cell Reports, Vol 22, Iss 10, Pp 2797-2807 (2018)
Summary: Transcription factor (TF) binding to DNA is crucial for transcriptional regulation. There are multiple methods for mapping such binding. These methods balance between input requirements, spatial resolution, and compatibility with high-throug
Externí odkaz:
https://doaj.org/article/d8f8baa4f4f64a3a895cab4ae35da467
Publikováno v:
JAMA network open. 5(6)
FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not b
Autor:
Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric Andrew Collisson, Michael Jordan Fisch, Dvir Aran
Publikováno v:
Journal of Clinical Oncology. 40:e16271-e16271
e16271 Background: The common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC) are FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem-Nab-P). However, these treatments have not been directly compared in a clinical trial and c
Publikováno v:
Journal of Clinical Oncology. 40:e21519-e21519
e21519 Background: In metastatic melanoma (MM) patients, nivolumab can be used as monotherapy or in combinations with ipilimumab. The combination therapy has been shown in a randomized clinical trial to provide survival benefit in BRAF mutant patient
Publikováno v:
Journal of Clinical Oncology. 40:e18767-e18767
e18767 Background: A recent clinical trial (Impassion131) showed that addition of atezolizumab to paclitaxel does not provide survival benefit for first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) patients. The study was i
Publikováno v:
Journal of Clinical Oncology. 40:e18765-e18765
e18765 Background: Eribulin is a commonly prescribed regimen for metastatic triple negative breast cancer (mTNBC) patients pre-treated with one or more chemotherapy regimens, although no clear survival benefit has been shown when compared to treatmen
Autor:
Adi Alajem, Oren Ram, Nir Friedman, Daphna Joseph-Strauss, Nitzan Bodenheimer, Jenia Gutin, Ronen Sadeh, Avital Klein-Brill
Publikováno v:
Cell Reports, Vol 22, Iss 10, Pp 2797-2807 (2018)
Cell Reports
Cell Reports
Summary Transcription factor (TF) binding to DNA is crucial for transcriptional regulation. There are multiple methods for mapping such binding. These methods balance between input requirements, spatial resolution, and compatibility with high-through
Publikováno v:
Cell Reports
Summary Nucleosome organization has a key role in transcriptional regulation, yet the precise mechanisms establishing nucleosome locations and their effect on transcription are unclear. Here, we use an induced degradation system to screen all yeast A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0bc11c1d11ecf42f92483fc67a0ed9f
http://edoc.mdc-berlin.de/18585/1/18585oa.pdf
http://edoc.mdc-berlin.de/18585/1/18585oa.pdf